

- Agnoli A, Xing G, Tancredi DJ, Magnan E, Jerant A, Fenton JJ. Association of Dose Tapering With Overdose or Mental Health Crisis Among Patients Prescribed Long-term Opioids. *JAMA*. 2021 Aug 3;326(5):411-419. doi: [10.1001/jama.2021.11013](https://doi.org/10.1001/jama.2021.11013). PMID: [34342618](https://pubmed.ncbi.nlm.nih.gov/34342618/); PMCID: [PMC8335575](https://pubmed.ncbi.nlm.nih.gov/pmc/articles/PMC8335575/).
- Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. *Cochrane Database Syst Rev*. 2011 Oct 5;(10):CD004147. doi: [10.1002/14651858.CD004147.pub4](https://doi.org/10.1002/14651858.CD004147.pub4). PMID: [21975742](https://pubmed.ncbi.nlm.nih.gov/21975742/).
- Bolívar HA, Klemperer EM, Coleman SRM, DeSarno M, Skelly JM, Higgins ST. Contingency Management for Patients Receiving Medication for Opioid Use Disorder: A Systematic Review and Meta-analysis. *JAMA Psychiatry*. 2021 Oct 1;78(10):1092-1102. doi: [10.1001/jamapsychiatry.2021.1969](https://doi.org/10.1001/jamapsychiatry.2021.1969). Erratum in: *JAMA Psychiatry*. 2022 Mar 1;79(3):272. Erratum in: *JAMA Psychiatry*. 2023 Nov 1;80(11):1176. PMID: [34347030](https://pubmed.ncbi.nlm.nih.gov/34347030/); PMCID: [PMC8340014](https://pubmed.ncbi.nlm.nih.gov/pmc/articles/PMC8340014/).
- Boscarino JA, Withey CA, Dugan RJ, Hu Y, Auciello J, Alfieri T. Opioid medication use among chronic non-cancer pain patients assessed with a modified drug effects questionnaire and the association with opioid use disorder. *J Pain Res* 2020;13:2697–705. PMID:33122939 <https://doi.org/10.2147/JPR.S275397>.
- Brennan MJ. The effect of opioid therapy on endocrine function. *Am J Med*. 2013 Mar;126(3 Suppl 1):S12-8. doi: [10.1016/j.amjmed.2012.12.001](https://doi.org/10.1016/j.amjmed.2012.12.001). PMID: [23414717](https://pubmed.ncbi.nlm.nih.gov/23414717/).
- Ciraulo DA and Knapp CM. The pharmacology of non-alcohol sedative hypnotics. In: Ries RK, et al., eds. *Principles of Addiction Medicine*, 4th edition. Philadelphia: Lippincott, Williams & Wilkins, 2009:103.
- Donegan D, Bancos I. Opioid-Induced Adrenal Insufficiency. *Mayo Clin Proc* 2018 Jul;93(7):937-944. doi: [10.1016/j.mayocp.2018.04.010](https://doi.org/10.1016/j.mayocp.2018.04.010). PMID: [29976376](https://pubmed.ncbi.nlm.nih.gov/29976376/).
- Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. *JAMA*. 2016 Apr 19;315(15):1624-45. doi: [10.1001/jama.2016.1464](https://doi.org/10.1001/jama.2016.1464). PMID: [26977696](https://pubmed.ncbi.nlm.nih.gov/26977696/); PMCID: [PMC6390846](https://pubmed.ncbi.nlm.nih.gov/pmc/articles/PMC6390846/).
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. *MMWR Recomm Rep* 2022;71(No. RR-3):1–95. DOI: <http://dx.doi.org/10.15585/mmwr.rr7103a1>.

- Dunn KE, Saulsgiver KA, Miller ME, et al. Characterizing opioid withdrawal during double-blind buprenorphine detoxification. *Drug Alcohol Depend*. 2015 Jun 01;151:47-55. doi: [10.1016/j.drugalcdep.2015.02.033](https://doi.org/10.1016/j.drugalcdep.2015.02.033). PMID: [25823907](https://pubmed.ncbi.nlm.nih.gov/25823907/).
- Garg RK, Fulton-Kehoe D, Franklin GM. Patterns of Opioid Use and Risk of Opioid Overdose Death Among Medicaid Patients. *Med Care*. 2017 Jul;55(7):661-668. doi: [10.1097/MLR.0000000000000738](https://doi.org/10.1097/MLR.0000000000000738). PMID: [28614178](https://pubmed.ncbi.nlm.nih.gov/28614178/).
- Gatchel R, Howard K. The Biopsychosocial Approach. *Pract Pain Manag*. 2008;8(4). <https://www.medcentral.com/pain/chronic/biopsychosocial-approach>.
- Gomes T, Greaves S, van den Brink W, et al. Pregabalin and the risk for opioid-related death: a nested case-control study. *Ann Intern Med*. 2018 Nov 20;169(10):732-4. doi: [10.7326/m18-1136](https://doi.org/10.7326/m18-1136). PMID: [30140853](https://pubmed.ncbi.nlm.nih.gov/30140853/).
- Gomes T, Juurlink DN, Antoniou T, et al. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. *PLoS Med*. 2017 Oct;14(10):e1002396. doi: [10.1371/journal.pmed.1002396](https://doi.org/10.1371/journal.pmed.1002396). PMID: [28972983](https://pubmed.ncbi.nlm.nih.gov/28972983/).
- Gordon KS, Manhapra A, Crystal S, Dziura J, Edelman EJ, Skanderson M, Kerns RD, Justice AC, Tate J, Becker WC. All-cause mortality among males living with and without HIV initiating long-term opioid therapy, and its association with opioid dose, opioid interruption and other factors. *Drug Alcohol Depend* 2020;216:108291. doi: [10.1016/j.drugalcdep.2020.108291](https://doi.org/10.1016/j.drugalcdep.2020.108291). PMID:[33011662](https://pubmed.ncbi.nlm.nih.gov/33011662/); PMCID: [PMC7644145](https://pubmed.ncbi.nlm.nih.gov/PMC7644145/).
- Hernandez I, He M, Brooks MM, et al. Exposure-response association between concurrent opioid and benzodiazepine use and risk of opioid-related overdose in Medicare Part D beneficiaries. *JAMA Netw Open*. 2018 Jun 1;1(2):e180919. doi: [10.1001/jamanetworkopen.2018.0919](https://doi.org/10.1001/jamanetworkopen.2018.0919). PMID: [30646080](https://pubmed.ncbi.nlm.nih.gov/30646080/).
- Indiana University Clinical Pharmacology Research Institute. Drug Interactions Flockhart Table. <https://drug-interactions.medicine.iu.edu/MainTable.aspx> Accessed online March 5, 2024.
- James JR, Scott JM, Klein JW, Jackson S, McKinney C, Novack M, Chew L, Merrill JO. Mortality After Discontinuation of Primary Care-Based Chronic Opioid Therapy for Pain: a Retrospective Cohort Study. *J Gen Intern Med*. 2019 Dec;34(12):2749-2755. doi: [10.1007/s11606-019-05301-2](https://doi.org/10.1007/s11606-019-05301-2). Epub 2019 Aug 29. PMID: [31468341](https://pubmed.ncbi.nlm.nih.gov/31468341/); PMCID: [PMC6854174](https://pubmed.ncbi.nlm.nih.gov/PMC6854174/).

- Jones, C.M. & McAninch, J.K. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. *Am. J. Prev. Med.* 49, 493–501 (2015).
- Krebs EE, Lorenz KA, Bair MJ, Damush TM, Wu J, Sutherland JM, Asch SM, Kroenke K. Development and Initial Validation of the PEG, a Three-item Scale Assessing Pain Intensity and Interference. *J Gen Intern Med* 2009 Jun; 24(6): 733-738. Published online 2009 May 6. doi: [10.1007/s11606-009-0981-1](https://doi.org/10.1007/s11606-009-0981-1). PMID: [19418100](https://pubmed.ncbi.nlm.nih.gov/19418100/); PMCID: [PMC2686775](https://pubmed.ncbi.nlm.nih.gov/PMC2686775/);
- Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, King J, Lindblad R, Liu D, Matthews AG, May J, Peavy KM, Ross S, Salazar D, Schkolnik P, Shmueli-Blumberg D, Stablein D, Subramaniam G, Rotrosen J. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. *Lancet.* 2018 Jan 27;391(10118):309-318. doi: [10.1016/S0140-6736\(17\)32812-X](https://doi.org/10.1016/S0140-6736(17)32812-X). Epub 2017 Nov 14. PMID: [29150198](https://pubmed.ncbi.nlm.nih.gov/29150198/); PMCID: [PMC5806119](https://pubmed.ncbi.nlm.nih.gov/PMC5806119/).
- Mark TL, Parish W. Opioid medication discontinuation and risk of adverse opioid-related health care events. *J Subst Abuse Treat.* 2019 Aug;103:58-63. doi: [10.1016/j.jsat.2019.05.001](https://doi.org/10.1016/j.jsat.2019.05.001). Epub 2019 May 5. PMID: [31079950](https://pubmed.ncbi.nlm.nih.gov/31079950/).
- Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database Syst Rev.* 2009 Jul 8;2009(3):CD002209. doi: [10.1002/14651858.CD002209.pub2](https://doi.org/10.1002/14651858.CD002209.pub2). PMID: [19588333](https://pubmed.ncbi.nlm.nih.gov/19588333/); PMCID: [PMC7097731](https://pubmed.ncbi.nlm.nih.gov/PMC7097731/).
- Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database Syst Rev.* 2014 Feb 6;2014(2):CD002207. doi: [10.1002/14651858.CD002207.pub4](https://doi.org/10.1002/14651858.CD002207.pub4). PMID: [24500948](https://pubmed.ncbi.nlm.nih.gov/24500948/); PMCID: [PMC10617756](https://pubmed.ncbi.nlm.nih.gov/PMC10617756/).
- Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. *Cochrane Database Syst Rev.* 2011 Apr 13;2011(4):CD001333. doi: [10.1002/14651858.CD001333.pub4](https://doi.org/10.1002/14651858.CD001333.pub4). PMID: [21491383](https://pubmed.ncbi.nlm.nih.gov/21491383/); PMCID: [PMC7045778](https://pubmed.ncbi.nlm.nih.gov/PMC7045778/).
- Peckham AM, Fairman KA, Sclar DA. All-cause and drug-related medical events associated with overuse of gabapentin and/or opioid medications: a retrospective cohort analysis of a commercially insured US population. *Drug Saf.* 2018 Feb;41(2):213-28. doi: [10.1007/s40264-017-0595-1](https://doi.org/10.1007/s40264-017-0595-1). PMID: [28956286](https://pubmed.ncbi.nlm.nih.gov/28956286/).

- Rice D, Corace K, Wolfe D, Esmailisaraji L, Michaud A, Grima A, Austin B, Douma R, Barbeau P, Butler C, Willows M, Poulin PA, Sproule BA, Porath A, Garber G, Taha S, Garner G, Skidmore B, Moher D, Thavorn K, Hutton B. Evaluating comparative effectiveness of psychosocial interventions adjunctive to opioid agonist therapy for opioid use disorder: A systematic review with network meta-analyses. PLoS One. 2020 Dec 28;15(12):e0244401. doi: [10.1371/journal.pone.0244401](https://doi.org/10.1371/journal.pone.0244401). PMID: [33370393](https://pubmed.ncbi.nlm.nih.gov/33370393/); PMCID: [PMC7769275](https://pubmed.ncbi.nlm.nih.gov/PMC7769275/).
- Rubinstein A, Carpenter DM. Elucidating risk factors for androgen deficiency associated with daily opioid use. Am J Med 2014 Dec;127(12):1195-201. doi: [10.1016/j.amjmed.2014.07.015](https://doi.org/10.1016/j.amjmed.2014.07.015). Epub 2014 Jul 22. PMID: [25063648](https://pubmed.ncbi.nlm.nih.gov/25063648/).
- Sacerdote P, Franchi S, Panerai AE. Non-analgesic effects of opioids: mechanisms and potential clinical relevance of opioid-induced immunodepression. Curr Pharm Des. 2012;18(37):6034-42. doi: [10.2174/138161212803582496](https://doi.org/10.2174/138161212803582496). PMID: [22747543](https://pubmed.ncbi.nlm.nih.gov/22747543/).
- Sun EC, Dixit A, Humphreys K, et al. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017 Mar 14;356:j760. doi: [10.1136/bmj.j760](https://doi.org/10.1136/bmj.j760). PMID: [28292769](https://pubmed.ncbi.nlm.nih.gov/28292769/).
- Tanum L, Solli KK, Latif Z, et al. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial. JAMA Psychiatry. 2017;74(12):1197–1205. doi:[10.1001/jamapsychiatry.2017.3206](https://doi.org/10.1001/jamapsychiatry.2017.3206).
- Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther. 2004 Sep-Oct; 11(5):354-65. doi: [10.1097/01.mjt.0000132250.95650.85](https://doi.org/10.1097/01.mjt.0000132250.95650.85). PMID: [15356431](https://pubmed.ncbi.nlm.nih.gov/15356431/).
- Von Korff M, Walker RL, Saunders K, et al. Prevalence of prescription opioid use disorder among chronic opioid therapy patients after health plan opioid dose and risk reduction initiatives. Int J Drug Policy 2017;46:90–8. PMID:28666143 <https://doi.org/10.1016/j.drugpo.2017.05.053>.
- Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 2015;156:569–76. PMID:25785523 <https://doi.org/10.1097/01.j.pain.0000460357.01998.f1>.